Incyte (INCY) Akcija Kursas
Incyte Kursas
Per pastaruosius 19 metus Incyte pajamos augo 31,7 % kasmet ir pasiekė 5,14 mlrd. USD. Pelnas akcijai augo 68,6 % per metus per pastaruosius 10 metus. Incyte grynoji marža 25,0 % yra sumažėjo palyginti su 31,8 % prieš kelerius metus. Incyte 12 mėn. konsensuso tikslinė kaina yra 130,00 USD, apie virš kursą 15,4 %. Iš 35 analitikų 18 rekomenduoja pirkti — bendras konsensusas yra Pirkti.
Incyte akcijos kaina
Incyte akcija ir akcijų analizė
Dažnai užduodami klausimai apie Incyte akciją
The business model of Incyte Corp revolves around discovering, developing, and commercializing novel medicines to address the needs of patients with serious diseases. As a leading biotechnology company, Incyte focuses on discovering and developing small molecule drugs that target specific biological pathways involved in diseases such as cancer and immune-inflammatory disorders. By leveraging its expertise in genomics and medicinal chemistry, Incyte aims to bring innovative treatments to market, improving patients' lives worldwide. Through collaborations and partnerships, Incyte also strives to expand its product portfolio and accelerate its pipeline of promising therapies.
Incyte Corp is primarily active in the biotechnology and pharmaceutical industries.
The main competitors of Incyte Corp in the market are Bristol-Myers Squibb Company, Novartis AG, and Merck & Co., Inc.
Incyte Corp is a leading biopharmaceutical company based in the United States. Founded in 1991, it has established a strong reputation in the field of drug discovery and development. Incyte Corp primarily focuses on the discovery, development, and commercialization of innovative therapies to address various unmet medical needs. Throughout its history, the company has been committed to advancing scientific knowledge, and it has successfully launched several drugs targeting different diseases. With a dedicated team of researchers and professionals, Incyte Corp continues to make significant contributions to the healthcare industry, aiming to improve the lives of patients worldwide.
Incyte Corp has achieved several significant milestones in its history. One notable achievement is the development and approval of its flagship drug, Jakafi® (ruxolitinib), by the U.S. Food and Drug Administration (FDA) in 2011. Jakafi® is the first and only FDA-approved treatment for certain types of rare blood cancers. Additionally, Incyte Corp has made advancements in the field of oncology with the discovery and development of multiple innovative drugs, aiming to improve the lives of patients with various types of cancer. The company continues to expand its pipeline and collaborate with leading research institutions, further establishing itself as a prominent player in the biopharmaceutical industry.
Incyte Corp is primarily present in various countries and regions globally. The company has a widespread presence in the United States, where its headquarters are located in Wilmington, Delaware. Additionally, Incyte Corp has established its significant presence in Europe, including countries such as the United Kingdom, Germany, France, Italy, and Spain. It has also expanded its operations in Asia-Pacific regions like Japan, China, and Singapore. Furthermore, Incyte Corp has been expanding its reach in Latin American countries such as Brazil and Mexico, as well as in Canada. Overall, Incyte Corp has a strong international presence, allowing it to cater to a global market.
Incyte Corp represents values centered around innovation, collaboration, and integrity. The company prioritizes scientific excellence and is dedicated to discovering and developing transformative medicines for patients. Incyte Corp fosters a corporate philosophy that emphasizes the importance of putting patients first, embracing diversity and inclusion, and maintaining high ethical standards. With a focus on research and development, Incyte Corp strives to make a positive impact on the lives of patients and the healthcare industry as a whole.
Analitikai šiuo metu nustato vidutinę Incyte akcijos tikslinę kainą 128,38 USD (mediana: 130,00 USD), t. y. +14,0 % palyginti su paskutine kaina. Konsensusas pagrįstas 35 analitikų reitingais.
35 analitikai šiuo metu vertina Incyte akciją: 18 rekomenduoja pirkti, 17 laikyti ir 0 parduoti. 2026 m. analitikai tikisi, kad Incyte gaus 5,94 mlrd. USD pajamų ir 3,41 USD pelno akcijai.
Pagal dabartinį kursą Incyte akcija kainuoja 100,50 EUR (112,61 USD).
Incyte akcija (INCY) kotiruojama 8 biržose, įskaitant: NASDAQ (INCY), London (0J9P.L), SIX (Zürich) (ICY.SW), Frankfurt (ICY.F), München (ICY.MU), Düsseldorf (ICY.DU).
Incyte Corp is a biopharmaceutical company that focuses on the discovery, development, and marketing of drugs to help patients with serious diseases. The company is headquartered in Wilmington, Delaware, USA, and operates subsidiaries in Europe and Asia. Its business model is based on developing therapies to combat serious diseases such as cancer, inflammation, and autoimmune diseases through targeted therapy that attacks specific molecules in the body to reduce tumor spread or inflammatory reactions. Incyte Corp has a wide range of products that treat various diseases, with its flagship product being Jakafi® (Ruxolitinib), a drug for treating myelofibrosis and polycythemia vera. It also has a strong pipeline of new drugs in development, including Itacitinib for treating graft-versus-host disease and INCMGA00012 for treating solid tumors. The company is investing in digitization and data analysis to optimize its research and development efforts, and has various business segments including research and development, sales and marketing, clinical studies, and others. It distributes its products directly to clinics and hospitals as well as indirectly through wholesalers and distribution partners, and has formed partnerships with other companies in the industry to enhance research and development and expand global market access. In summary, Incyte Corp is dedicated to discovering, developing, and marketing drugs for patients with serious diseases, with a broad product range, strong partnerships, and a pipeline of new drugs in development. The company is dedicated to using data to improve patient care.
tikėtina pelnas Incyte yra 5,94 mlrd. USD. Šis skaičius grindžiamas dabartiniais finansiniais duomenimis ir atspindi įmonės verslo rezultatus.
tikėtina grynasis pelnas Incyte yra 697,46 mln. USD. Grynasis pelnas atspindi įmonės pelningumą po visų išlaidų atimties.
Kainų ir nuomos santykis (KGV) Incyte šiuo metu yra 33,06. KGV lygina dabartinę akcijos kainą su pelnu už akciją ir padeda investuotojams įvertinti Incyte akcijos vertę.
Kainų ir pardavimų santykis (KUV) Incyte šiuo metu yra 3,88. KUV lygina rinkos kapitalizaciją su metinėmis pajamomis ir yra Incyte akcijos įvertinimo metrika.
Eulerpool kokybės balas Incyte yra 6/10.
Incyte ISIN yra US45337C1027. ISIN (International Securities Identification Number) yra pasaulinė unikali vertybinių popierių identifikacijos sistema.
Incyte WKN yra 896133. WKN (Wertpapierkennnummer) yra šešiaženklė vokiška vertybinių popierių identifikacijos sistema.
Incyte prekybos žymė yra INCY. Ši biržos žymė naudojama Incyte akcijoms prekiauti biržoje.
Incyte akcija
Incyte Pagrindiniai konkurentai
Incyte Biržos simbolis
Incyte FIGI
Visos Incyte pagrindinės charakteristikos ir giluminė analizė
Mūsų akcijų analizė Incyte akcijai apima svarbius finansinius rodiklius, tokius kaip apyvarta, pelnas, P/E santykis, P/S santykis, EBIT, taip pat informaciją apie dividendes. Be to, mes nagrinėjame aspektus, tokius kaip akcijos, rinkos kapitalizacija, skolos, nuosavas kapitalas ir įsipareigojimai Incyte. Jei ieškote išsamesnės informacijos šiais klausimais, mūsų poskyriuose galite rasti išsamias analizes: